Phase 1/2CompletedGeroscience intervention

Evaluation of Fisetin to Reduce Systemic Senescence

Evaluation of Fisetin to Reduce Systemic Senescence Indices: A Randomized Controlled Dosing Equivalence Study

Sponsor
Steadman Philippon Research Institute (Academic or other)
Enrollment
82 enrolled
Conditions
Cellular Senescence
Interventions
Fisetin (daily dosing); Fisetin (bolus dosing)
Ages
adults, older adults
Registry
NCT07918261

Full record on ClinicalTrials.gov

From the registry

This is a prospective, randomized clinical trial to evaluate the ability of the supplement, Fisetin, to safely reduce systemic senescence (aging) indices assessed in peripheral blood.

Primary outcomes

  • Change from baseline in levels of senescent PBMCs (total and specific PBMC subsets such as T-Cells)

History

  1. Registered

  2. Primary completion

  3. Started